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SUMMARY We previously demonstrated that a  1 Mb
domain of genes upstream of and including Hoxa13 is co-
expressed in the developing mouse limbs and genitalia. A highly
conserved non-coding sequence, mmA13CNS, was shown to
be insufficient in transgenic mice to direct precise Hoxa13-like
expression in the limb buds or genital bud, although some LacZ
expression from the transgene was reproducibly found in these
tissues. In this report, we used b-globin minimal promoter LacZ
recombinant BAC transgenes encompassing mmA13CNS to
identify a single critical region involved in mouse Hoxa13-like
embryonic genital bud expression. By analyzing the expression
patterns of these overlapping BAC clones in transgenic mice,
we show that at least two sequences remote to the HoxA cluster
are required collectively to drive Hoxa13-like expression in
developing distal limbs. Given that the paralogous posterior
HoxD and neighboring genes have been shown to be under the
influence of long-range distal limb and genital bud enhancers,
we hypothesize that both long-range enhancers have one
ancestral origin, which diverged in both sequence and function
after the HoxA/D cluster duplication.
INTRODUCTION
Hox genes encode transcription factors that are conserved
among all vertebrates and are essential for appropriate axial
and appendicular embryonic patterning (McGinnis and
Krumlauf 1992; Veraksa et al. 2000). Over the course of ver-
tebrate evolution, a single ancestral Hox cluster underwent
individual gene, and entire cluster, duplications leading to 39
Hox genes organized into four clusters (HoxA–HoxD) char-
acteristic of all mammals (Kappen et al. 1989; Ruddle et al.
1994; Prince 2002). During embryonic axial patterning the
Hox genes are colinearly expressed, both spatially and
temporally (Duboule and Morata 1994). For appendicular
patterning, the posterior HoxA and HoxD genes are re-
expressed in the presumptive appendicular tissues. Specifi-
cally, the Abd-B derived genes in the posterior HoxA and
HoxD clusters are necessary for limb and urogenital devel-
opment (Fromental-Ramain et al. 1996; Mortlock and Innis
1997; Warot et al. 1997; Zakany et al. 1997). Mutations in
human HOXA13 are associated with dominantly inherited
hand-foot-genital syndrome (HFGS; OMIM #140,000)
(Mortlock and Innis 1997; Goodman et al. 2000) which is
characterized by malformations of the distal limbs as well
as urogenital structures. Similar malformations were also
observed in the spontaneous mouse mutant, Hypodactyly
(Mortlock et al. 1996), and in engineered Hoxa13 null mouse
models (Fromental-Ramain et al. 1996; Stadler et al. 2001).
The function of posterior HoxA and HoxD genes in
developing appendicular structures is believed to have been
acquired secondarily to the primary, ancestral role of all four
clusters in axial patterning (Herault et al. 1998; Spitz et al.
2001). Regulatory sequences responsible for the expression of
the HoxD genes in the developing limb buds and genital bud
have been mapped to locations remote from the cluster (Spitz
et al. 2001; Spitz et al. 2003; Gonzalez et al. 2007), and we
have hypothesized that the HoxA cluster is under a similar
mode of regulation (Lehoczky et al. 2004). In previous work,
we showed that a set of genes upstream of Hoxa13, (Evx1,
Hibadh, Tax1bp1, and Jazf1), are expressed in Hoxa13-like
distal limb and genital bud domains between E10.5 and E13.5
(Lehoczky et al. 2004). We hypothesized that a broadly acting
enhancer is responsible for the shared spatial and temporal
gene expression patterns. In addition, we hypothesized that
the enhancer exerts function over a finite domain because
genes immediately proximal and distal to the neighborhood
(Hoxa11 andCrebpa, respectively) are not expressed similarly.
A similar global enhancer has been described for theHoxD
locus (Spitz et al. 2003; Gonzalez et al. 2007). At this locus,
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Evx2 and Lnp are expressed in the distal limb and genital bud
in a spatial and temporal pattern common to the posterior
HoxD genes. Given that the four mammalian Hox clusters are
derived from a single ancestral cluster, we hypothesized that a
single regulatory innovation occurred in the HoxA/D lineage
before cluster duplication. This regulatory mechanism was
retained by both the HoxA and HoxD clusters, driving pos-
terior HoxA/D gene expression in the developing append-
icular and urogenital structures. Results of comparative
sequence analysis supported our hypothesis, as five paralo-
gously conserved (HoxA locus vs. HoxD locus) non-coding
DNA sequences (putative regulatory elements) are shared
between the HoxA/D upstream regions (paraCNS1-5)
(Lehoczky et al. 2004). No similar sequence conservation
was found between HoxA/D and the HoxB or HoxC
genomic regions. This is consistent with absence of posterior
HoxB/C expression in the HoxA/D expression domains of
distal limbs and genital bud (though Hoxc13 is expressed in
the nail beds of the distal limbs (Godwin and Capecchi 1998;
Godwin et al. 1998)). On theHoxA chromosome, paraCNS4
and 5 map to a conserved 2.25 kb element (mmA13CNS)
and they also correspond to the ‘‘distal limb enhancer’’
critical region on the HoxD chromosome (Spitz et al. 2003).
We tested the ability of mmA13CNS to direct LacZ expres-
sion in the developing limbs and urogenital system and
found that mmA13CNS was insufficient for appropriate
posterior HoxD-like/Hoxa13-like distal limb or genital
bud expression. Although inappropriate LacZ expression
was reproducibly found in those tissues, in multiple lines, we
hypothesized that mmA13CNS may function in Hoxa13
tissue-specific expression, but additional surrounding
sequences were necessary for appropriate expression.
In this report, we created transgenic mice with BACs
encompassing mmA13CNS with b-globin LacZ reporters in
cis to examine our hypothesis and to begin to identify broad
enhancer domains within which to focus future attention. By
deduction, expression from overlapping BAC clones allowed
us to demonstrate the involvement of a single critical region
for Hoxa13-like embryonic genital bud expression. By con-
trast, the same BACs illustrate the existence of at least two
separate loci remote to the HoxA cluster involved in Hoxa13-
like distal limb expression from E10.5 to E13.5.
MATERIALS AND METHODS
LacZ expression from mmA13CNS mouse transgenic lines gener-
ated with b-globin-LacZ (data not shown) corroborated the ex-
pression found from the Hsp68-LacZ lines (Lehoczky et al. 2004).
Both constructs were insufficient to drive appropriate Hoxa13-like
distal limb or genital bud expression at any embryonic stage. We
concluded that the two minimal promoters were comparable for
the purposes of our experiments and proceeded to use the b-globin
minimal promoter LacZ construct for all future experiments.
BAC modification
BAC clones from the HoxA locus RPCI-23-347D13 and RPCI-23-
420L19 (BACPAC Resources) were identified by end sequences
AZ032610, AZ032607, AZ068097, and AZ068091 (www.tigr.org).
Original clones were both fingerprint (NotI and EcoRI) and PCR
verified to assure identity and structure. The minimal promoter
LacZ reporter cassette, pFNeoH1H2bglob-LacZ, was constructed
to target the sacB gene in the pBACe3.6 backbone in either BAC.
The neo cassette flanked by FRT sites cloned into the SmaI site of
pBKS was obtained (gift of J. D. Engel) and modified to insert
the b-globin minimal promoter LacZ reporter (kindly provided by
R. Krumlauf) into the SalI site.
BAC homology arms H1 and H2 were individually PCR
amplified with restriction site tailed primers (H1_PmeI TTGTTTA
AACGTTACGACTGCACTTCTGG, H1_PacI.R TTTTAATTA
ACGAATTGAGGCACTTGGT, H2_XhoI.F AACTCGAGCG
ATATTTACATGCTTGGTT, and H2_KpnI.R AAGGTACCCA
TGTAGCTTGTGATAACCA) and directionally cloned into the
targeting construct. The linear fragment for recombineering
was generated from the resultant clone by insert excision with a
PmeI/KpnI double digest followed by gel purification. Targeting of
the linear fragment into the BAC vector was done as previously
reported (Yu et al. 2000; Lee et al. 2001; Khandekar et al. 2004)
with the following exceptions. EL250 (kindly provided by N. A.
Jenkins and N. G. Copeland) heat induced, electrocompetent cells
(100ml culture) were prepared when the density of the culture
reached an A600 of 0.2. The culture was centrifuged 15min at
10,000 rpm at 41C and the resultant pellet was resuspended in 10ml
of ice cold 10% glycerol. This was repeated four times and the final
pellet was resuspended in 100–200ml of 10% glycerol. One hundred
nanograms of the linear targeting construct was electroporated into
25ml of freshly prepared, heat-induced cells. Clones that were
chloramphenicol- and kanamycin-resistant were verified by PCR
for the presence of the targeting event, and were used for
subsequent arabinose induction of flp recombinase to excise the
neo cassette. Resultant clones that were chloramphenicol-resistant
and kanamycin-sensitive were both fingerprint and PCR verified to
assure that the intended recombinant clones were obtained.
Transgenic mice and LacZ embryo staining
BAC transgene preparation was performed by standard alkaline
lysis protocols followed by sepharose-CL-4B column purification
as previously described (Yang et al. 1997). Undigested BAC trans-
gene DNA was microinjected into (C57BL/6  SJL) F2 fertilized
eggs at  1ng/ml (University of Michigan TAMC). All DNA
samples extracted from yolk sacs or tail snips were genotyped for
the BAC insert/BAC vector SP6 junction as well as the b-globin/
LacZ junction. The preliminary 347D13-LacZ transgene microin-
jection was used for an E12.5 founder embryo harvest. This
injection yielded five transgenic of 80 total embryos, two of which
had LacZ expression. Additional 347D13-LacZ microinjections
were performed to obtain permanent lines. Eight transgenic
founders were obtained from a total of 331 pups. Three founder
lines were used for timed embryo analysis (three founders did not
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pass the transgene through the germline and two founder lines did
not express the transgene). A single 420L19-LacZ transgene
microinjection was performed and yielded 10 transgenic animals
out of 108 total offspring. Seven founder lines were used for timed
embryo analysis (two founders did not transmit the transgene and
one founder line did not express the transgene). All timed matings
and LacZ embryo staining were carried out as previously described
(Lehoczky et al. 2004).
BAC transgene contribution analysis
Because the BAC clones were derived from the C57Bl/6 mouse
strain, the transgenic lines were crossed onto a polymorphic strain
to assess, by SNP analysis, what portion(s) of BAC transgene had
integrated into the genome. Four 347D13-LacZ and seven 420L19-
LacZ transgenic lines were individually crossed onto the DBA2/J
strain, which is polymorphic relative to C57Bl/6J throughout and
upstream of theHoxA locus. In all cases, F1 litters were genotyped
for the presence of the transgene and these positive animals were
obligate DBA2/J heterozygotes. Transgene1/ ; DBA1/
animals were subsequently backcrossed onto the DBA2/J strain
and N1 litters were once again screened for the presence of the
appropriate transgene. Transgenic DNA samples were then geno-
typed for the C57/SJL/DBA polymorphic SNPs, RS3023069 and
RS13478756, positioned adjacent to the endogenous region from
which the BAC clones were derived. Resultant DNA samples that
were transgenic and DBA congenic for the upstream HoxA region
were used to PCR amplify across SNPs throughout the region of
the BAC transgene. SNPs RS29851258, RS29857058, RS30707421,
RS13478755, RS29863749, and RS30170317 were used for the
347D13-LacZ lines and only the latter three were used for the
420L19-LacZ lines (supplementary Fig. S3). Lines 250 and 268
were excluded from this analysis due to repeated unsuccessful
attempts to generate transgenic DBA1/1animals. PCR products
were directly sequenced (University of Michigan Sequencing Core),
and resultant chromatograms were visually inspected for the DBA
SNP only (no transgene contribution), or DBA/C57 SNP (trans-
gene contribution).
Transgene copy number analysis was performed with phenol/
chloroform prepared spleen DNA from N1 or N2 C57Bl/6J back-
cross animals. Southern blots were prepared by standard methods.
In brief, 10mg of transgenic or C57Bl/6J wild-type genomic DNA
was digested with EcoRI to completion. Before electrophoresis,
EcoRI digested pBACe3.6 vector was spiked in fixed amounts into
the wild-type digests to serve as transgene copy number controls.
An EcoRI/KpnI pBACe3.6 fragment was used for random
hexamer primed labeling with 32P-dATP. Blot hybridization and
washing was performed by standard methods. Transgene copy
number was determined by relative densitometry using the publicly
available ImageJ software (NIH).
RESULTS
In this report, we compare transgenic expression to the
endogenous expression patterns of Hoxa13 in the limbs and
genital bud, yet we believe our transgenic expression data
reflects the entire Hoxa13 neighborhood of genes (Evx1,
Hibadh, Tax1bp1, and Jazf1) (Lehoczky et al. 2004). We use
Hoxa13 expression as the representative gene for comparison
because of its established necessity in limb and genital devel-
opment. Endogenous expression of Hoxa13 for stages E10.5–
E13.5 is presented in supplementary Fig. S1.
BAC 347D13-LacZ is sufficient for proper
Hoxa13-like expression
To address the hypothesis that additional sequences in the
vicinity of mmA13CNS are needed for appropriate Hoxa13-
like distal limb expression, we obtained a  220kb mouse
BAC clone, RPCI-23-347D13, which overlaps mmA13CNS
by a wide margin (  73kb on one side and  145kb on the
other) skewed toward the HoxA cluster (Fig. 1). We used
homologous recombination to place the b-globin-LacZ
reporter construct into the BAC vector backbone (Yu et al.
2000; Lee et al. 2001; Khandekar et al. 2004) and used the
resultant recombinant BAC, 347D13-LacZ, for transgenic
microinjection. E12.5 founder embryos were harvested and
three of five transgenic founders had no LacZ expression in
any tissue and were thus excluded from the analysis. The two
remaining embryos both had LacZ expression in the central
nervous system, limbs, and genital bud. The expression
pattern found in the hindbrain and neural tube of both
embryonic founders was consistent with the original
mmA13CNS transgene expression (Lehoczky et al. 2004).
We used this central nervous system Evx1-like (not Hoxa13)
pattern of expression as a positive control for expression from
the injected transgene.
The expressing founder embryos showed Hoxa13-like
distal limb and genital bud LacZ expression. Autopod
expression in the fore- and hindlimbs of founder 69 at E13
was virtually identical to the expected Hoxa13 expression
domain (Fig. 1, B, C, F and G and supplementary Fig. S1)
(Haack and Gruss 1993; Mortlock et al. 1996; Innis et al.
2004; Lehoczky et al. 2004; Williams et al. 2005). Expression
in the genital bud was posteriorly restricted (discussed in later
section; data not shown, similar to Fig. 4E0). The limb
expression in founder 18 was restricted to the posterior
autopod (discussed in later section; shown in supplementary
Fig. S2), yet genital bud staining was appropriate when com-
pared with endogenous expression of Hoxa13 (Fig. 1D and
H) (Stadler et al. 2001; Lehoczky et al. 2004; Scott et al. 2005).
Collectively, these embryos demonstrate that 347D13-LacZ is
sufficient for E12.5 Hoxa13-like expression in the distal limb
and genital bud.
To further interrogate the ability of 347D13-LacZ to direct
Hoxa13-like expression at additional developmental stages,
we repeated the transgene injection and generated three
permanent lines (8, 710, and 733). Lines 8 and 733, while
exhibiting the expected central nervous system LacZ staining
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pattern, had no additional LacZ activity at any stage (data
not shown). In contrast, line 710 had strong distal limb and
genital bud LacZ expression in addition to the expected
central nervous system staining between stages E10.5 and
E13.5 (Fig. 2, A, D, H, L, P, and T). A description of stage-
specific LacZ expression in this line follows and the data is
summarized in Table 1.
At E10.5, line 710 expresses the 347D13-LacZ transgene in
the distal forelimb and the ventral, distal trunk mesenchyme
surrounding the hindlimbs, urogenital tissues, and tail. Fore-
limb expression is largely similar to the endogenous E10.5
RNA expression domain of Hoxa13, with appropriate ante-
rior/posterior boundaries and distal placement (Fig. 2B
arrowhead). Therefore, 347D13-LacZ is sufficient for E10.5
Hoxa13-like distal forelimb expression. The LacZ expression
pattern found in the trunk is not consistent with the known
E10.5 expression of Hoxa13 or any of the genes in the
Hoxa13 expression neighborhood (Evx1, Hibadh, Tax1bp1,
and Jazf1). However, expression does encompass the expected
genital bud domain ofHoxa13, so in addition to its additional
activity, 347D13-LacZ is sufficient for Hoxa13-like genital
bud expression (Fig. 2C).
The sufficiency of 347D13-LacZ to drive Hoxa13-like
distal forelimb expression is maintained through E11.5 where
the LacZ expression remains restricted to the distal boundary
and extends to appropriate Hoxa13-like anterior/posterior
boundaries of the autopod (Fig. 2E). The broad trunk
staining from the previous stage becomes strikingly restricted
to the mesenchyme of the developing genital bud at E11.5 as
is expected for the endogenous expression of Hoxa13. Thus,
the transgene is sufficient for E11.5 Hoxa13-like forelimb and
genital bud expression. The hindlimb expression in this line is
not sufficient for complete Hoxa13-like limb expression
(Fig. 2F). While the proximal/distal boundaries are appro-
priate, the anterior/posterior expression boundaries are
posteriorized.
For stages E12.0–E12.5 in line 710, 347D13-LacZ is suffi-
cient forHoxa13-like expression in the developing genital bud
(Fig. 2, K and O). This corroborates the results obtained from
founder 18 (Fig. 1D). In contrast, the limb staining is not
consistent between line 710 and either founder embryo (69 or
18) (Fig. 2, I, J, M, and N). Instead, this expression, while
appropriate at the distal boundary, extends beyond the
expected posterior and proximal boundaries. In addition, in
comparison to endogenous Hoxa13, the transgenic LacZ
expression domain does not completely extend into the
anterior autopod. Variation in expression patterns among
founders and lines is common in such experiments and can be
due to complexity in the BAC transgene insert DNA config-
uration and/or genomic site effects.
At E13.0–E13.5 347D13-LacZ in line 710 remains sufficient
for Hoxa13-like genital bud expression (Fig. 2, S and W).
Fig. 1. (Top) To-scale representation of the 1Mb region of mouse chromosome 6 upstream of the HoxA cluster that is under the influence
of a long-range distal limb and genital bud enhancer module. Base 1 is the first nucleotide adjacent to the Hoxa11 promoter and base
1041528 is the nucleotide before the start of the 50 UTR of Creb5. Red arrowhead denotes the position of mmA13CNS, found within intron
4 of Hibadh. 347D13 and 420L19 are the two BAC clones used in this report. (Bottom) (A–C) X-gal stained E12.5–E13.0 347D13-LacZ
founder embryo 69 and (D) E12.0–E12.5 347D13-LacZ founder embryo 18. LacZ expression was detected in the distal autopod and genital
bud in aHoxa13-like pattern (E–H). Central nervous system LacZ expression was also found in both transgenic embryos in an Evx1/Evx2-
like pattern, albeit at a weaker level in founder embryo 69 (A).
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Fig. 2. Timed embryo analysis of LacZ expression in a 347D13-LacZ transgenic mouse line 710. This transgene insertion drives distal limb
and genital bud LacZ expression similar, but not identical, to the expression pattern of Hoxa13. All embryos were stained with X-gal and
photographed with distal positioned to the top and anterior positioned to the left. Embryos were analyzed at multiple stages: (A–C) E10.5,
(D–G) E11.5, (H-K) E12.0, (L–0) E12.5, (P–S) E13.0, and (T–W) E13.5. B, E, I, M, Q, and U, are the forelimbs, photographed at a higher
magnification, of embryos in A, D, H, L, R, and T, respectively. Black arrowhead in panel B shows distal autopod expression domain.
(U inset) Eosin counter-stained cross-section of X-gal stained forelimb at level of black arrowhead with dorsal to the top and ventral to the
bottom. C, F, J, N, R, and V are the stained hindlimbs and G, K, O, S, and W are the stained genital buds (circled).
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The expression remains concentrated in the genital bud me-
senchyme and has appropriate anterior/posterior boundaries.
However, at this stage line 710 does not exhibit complete
distal fore- or hindlimb Hoxa13-like transgene expression
(Fig. 2, Q, R, U and V). As was seen with the previous stage,
limb staining extends to the distal tip of the autopod but
does not reach the expected anterior boundary, and reporter
expression extends beyond the expected posterior and prox-
imal boundaries. In addition, at this stage there is minor
regression of reporter activity in the anterior/central auto-
pod. It is unclear whether this regression is similar to that of
endogenous HOXA13 protein, but a similar regression of
reporter expression was observed in the autopods of Hoxa13-
GFP mice at similar stages (Stadler et al. 2001). Despite the
skewed expression domains on the other axes, the expression
on the dorsal/ventral axis is appropriate (Fig. 2U inset), as
was true with the earlier stages (data not shown). Thus, line
710 demonstrates appropriate early expression of the trans-
gene reporter, however, later expression domains are skewed
in the autopod along the anterior/posterior and proximal/
distal axes. Yet, complete Hoxa13-like expression of this
transgene at E12.5–E13.0 in founder 69 suggests sufficiency at
this stage for appropriate proximal/distal, anterior/posterior
and dorsal/ventral expression.
BAC 420L19-LacZ is partially sufficient for
Hoxa13-like expression
In order to better define sequences responsible for directing
Hoxa13-like expression, we selected another BAC clone,
RPCI-23-420L19 that overlaps with mmA13CNS by a wide
margin (  38kb to one side and  139kb to the other), but
is skewed further away from the HoxA cluster and overlap-
ping RPCI-23-347D13 by 114kb (Fig. 1). We modified this
BAC to contain the b-globin-LacZ minimal reporter in cis and
used the resultant construct, 420L19-LacZ, to create trans-
genic mice. Seven expressing transgenic lines (215, 222, 237,
250, 267, 268, and 273) were used for timed embryo analysis.
Embryos from all seven lines were collected between stages
E10.5 and E13.5 and analyzed for LacZ expression. Com-
bined results from all lines revealed this transgene was capable
of expressing LacZ in the distal limbs and the genital bud, as
well as the expected domains of the central nervous system
(Fig. 3, A, C, G, K, O, and S). As previously mentioned,
central nervous system LacZ activity was used to gauge if our
transgenic lines (either 347D13-LacZ or 420L19-LacZ) were
expressing the incorporated transgene. While this served as a
suitable positive control, we still observed inter-line differences
in timing/onset, levels, and domains of LacZ expression in the
developing genital bud and limbs (Fig. 4 and supplementary
Fig. S2). While there was inter-line variation, line 215 was
representative of the expression timing and distribution of all
420L19-LacZ lines, and thus we present it here as an example
of the enhancer capabilities of 420L19-LacZ. We conclude
that 420L19-LacZ is sufficient for Hoxa13-like genital bud
expression at E10.5 and E11.5, yet insufficient for this com-
plete expression from E12.5 to E13.5. We also conclude that
this transgene is insufficient for complete Hoxa13-like distal
limb expression at any stage. Detailed stage-specific LacZ
expression follows and all results are summarized in Table 1.
At E10.5, 420L19-LacZ embryos have no discernible fore-
limb LacZ expression (Fig. 3A). As was seen with 347D13-
LacZ, these embryos have a broad region of distal/ventral
trunk LacZ expression, encompassing both the presumptive
hindlimbs and the urogenital tissues but not the tail (Fig. 3B).
This expression, while not identical to the expected Hoxa13
genital bud expression, does encompass the expected Hoxa13
expression domain. We conclude that 420L19-LacZ is suffi-
cient to direct expression in the genital mesenchyme and
insufficient for forelimb expression at E10.5.
At E11.5, consistent with 347D13-LacZ, 420L19-LacZ re-
porter expression in the caudal/ventral mesenchyme becomes
excluded from the surrounding tissues and is solely expressed
in the genital bud (Fig. 3F). This property was observed for
both transgenes and may represent a true capability of the
enhancer module that is used or modified in the endogenous
locus in a promoter-specific manner. The expression in the
genital bud appears identical to the expected endogenous
pattern ofHoxa13RNA, thus we conclude that 420L19-LacZ
is sufficient for Hoxa13-like genital bud expression at E11.5.
In contrast, this transgene is insufficient for appropriate
Hoxa13-like distal limb expression. LacZ expression is found
in both fore- and hindlimbs (Fig. 3, D and E), yet the domain
Table 1. Summary of LacZ expression from BAC
transgenic lines
CNS
Distal limbs Genital bud
E10.5 E11.5 E12.5 E13.5 E10.5 E11.5 E12.5 E13.5
347D13-
LacZ
8 Y N N N N N N N N
18 Y ? P ? ? ? Y ? ?
69 Y ? ? Y ? ? ? P ?
710 Y Y Y P P Y Y Y Y
733 Y N N N N N N N N
420L19-
LacZ
215 Y N P P P Y Y P P
222 N N N N P N N N N
237 Y N P P P Y P P P
250 Y N P P P Y P P P
267 Y N P P P Y P P P
268 Y N N P P N N N N
273 Y N N N N N N N N
Y, appropriate expression; P, partial expression; N, no expression;
?, not done.
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Fig. 3. Timed embryo analysis of LacZ expression in a 420L19-LacZ transgenic mouse line 215. This transgene is capable of expressing
LacZ in a peripheral subdomain of the expected Hoxa13 expression pattern in the autopod and genital bud. All embryos were stained with
X-gal and photographed with distal positioned to the top and anterior positioned to the left. Embryos were analyzed at multiple stages:
(A and B) E10.5, (C–F) E11.5, (G–J) E12.0, (K–N) E12.5, (O–R) E13.0, and (S–V) E13.5. A, D, H, L, P, and T are the forelimbs,
photographed at a higher magnification, of embryos in A, C, G, K, O, and S, respectively. (T inset) Eosin counter-stained cross-section of
X-gal stained forelimb at level of black arrowhead with dorsal to the top and ventral to the bottom. B, E, I, M, Q, and U are the stained
hindlimbs and F, J, N, R, and V are the stained genital buds (circled) at these stages. Note there is no expression in forelimbs at stage E10.5.
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is posteriorly restricted. In addition to the incorrect anterior/
posterior boundaries, the proximal/distal boundaries are also
misplaced. The 420L19-LacZ expression domain extends past
the appropriate proximal boundary (arrowhead Fig. 3D), and
does not extend to the distal-most region of the autopod. This
transgenic expression domain represents only a small poste-
rior subdomain of the expected Hoxa13 expression pattern,
thus we conclude that sequences within 420L19-LacZ are
insufficient for Hoxa13-like E11.5 autopod expression.
Between stages E12.0 and E12.5, 420L19-LacZ no longer
directs Hoxa13-like genital bud expression. In the transgenic
embryos, LacZ expression is only seen in the posterior half
of the tubercle (Fig. 3, J and N), whereas the endogenous
expression of Hoxa13 is found throughout the entire genital
bud at this stage. In addition, we conclude that this transgene
is insufficient for Hoxa13-like distal limb expression between
E12.0 and E12.5. At E12.0, anterior and distal Hoxa13-like
LacZ domains begin to be expressed in addition to a broad-
ening of the posterior expression domain from the previous
stage (Fig. 3, H, I, L, and M). This LacZ expression is
in conflict with many aspects of the endogenous Hoxa13
expression pattern. While there is expression in both the an-
terior and posterior portions of the autopod, there is absence
of LacZ expression throughout the central autopod. In
addition, the proximal/distal boundaries are inappropriate.
LacZ expression never reaches the distal tip of the autopod,
leaving a thin strip of non-expressing mesenchyme, and LacZ
expression extends too far proximally.
At stages E13.0 and E13.5, the conclusions drawn at E12.5
were corroborated. 420L19-LacZ is insufficient for complete
Hoxa13-like genital bud expression (Fig. 3, R and V). The
LacZ staining, while partially appropriate, is posteriorly re-
stricted and only represents half of the endogenous Hoxa13
expression pattern. In addition, the distal limb LacZ expres-
Fig. 4. Representative E10.5–E13.5 geni-
tal bud LacZ expression common to both
lines 347D13-LacZ and 420L19-LacZ.
Embryos are pictured with anterior to
the left. When any genital bud expression
was present at E10.5–E11.5 in embryos
from either transgene it was consistently
expressed in the same domains (A and B).
Between stages E11.5–E13.5, both BAC
transgenes were observed to have expres-
sion in the genital bud in two different
ways: (C, D, and E) complete Hoxa13-
like genital bud expression or (C0, D0,
and E0) posteriorized Hoxa13-like genital
bud expression. (F) Shows ventral views
of genital buds of line 710 (BAC 347D13)
and lines 215 and 237 (BAC 420L19).
Tails were removed from all embryos
presented in (F); hindlimbs were removed
from the E13.5 embryos. Anterior is up.
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sion only represents a portion of the stage-appropriate
Hoxa13 expression (Fig. 3, P, Q, T, and U). While the
expression does extend to the correct anterior/posterior and
dorsal/ventral boundaries (as is true at all stages, Fig. 3T
inset), expression throughout the central autopod is absent. In
addition, the proximal/distal boundaries are still skewed such
that the LacZ expression domain does not extend to the
distal-most tip of the autopod, and the proximal boundary
extends past the expected boundary into the zeugopod.
Because of the ability of this transgene to recapitulate some,
but not all, endogenous Hoxa13 expression domains of the
autopod, we conclude that 420L19-LacZ is insufficient for
Hoxa13-like distal limb expression at any stage. We also con-
clude that 420L19-LacZ is sufficient for Hoxa13-like genital
bud expression at E10.5 and E11.5, yet insufficient for this
complete expression from E12.5 to E13.5.
Transgene integrity
Analyzing all of the 347D13-LacZ/420L19-LacZ lines
collectively (supplementary Fig. S2) enabled us to tease out
different aspects of the transgenic expression, namely: timing
of expression onset, posterior and anterior expression
domains, distal and proximal expression boundaries, and
central autopod expression domain. To address whether the
differences found between our BAC transgenes and between
lines of the same transgene were due to technical issues arising
from the transgene injection/insertion or to subtleties in the
function of the enhancer(s), we pursued experiments to
determine BAC copy number and to validate the integrity of
the transgenes. By Southern hybridization, we quantified
the number of integrated transgenes in fully constituted, N1
transgenic animals. We found that among our transgenic
lines, there is no correlation between transgene copy number
and level of LacZ expression (supplementary Table S1).
Because BAC transgene copy number was not playing a
significant role in the inter-line expression variation, we
turned to analyzing the integrity of the incorporated trans-
gene by polymorphic SNP analysis (see ‘Materials and meth-
ods’). Results from this analysis for 347D13-LacZ transgenic
lines correlated well with the LacZ expression. Lines 8 and
733 had LacZ expression in the central nervous system and no
additional tissues. Marker analysis showed that in both of
these cases the incorporated BAC was fragmented into at
least two (line 8) or three pieces (line 733) and large portions
of the transgene missing (supplementary Fig. S3). These lines
were excluded from the analysis.Line 710 contained the entire
BAC as assessed by markers A–D and F–I (supplementary
Fig. S3). This analysis could not be done for the two founder
embryos. Because circular BAC clones were used as the sub-
strate for microinjection, random BAC breakage must have
occurred before integration of the transgene into the genome.
Our analysis did not determine the structure of the transgene
integration and does not rule out a microdeletion between any
two of the retained markers upon transgene breakage. Thus,
the anterior and central autopod expression loss observed late
in this line cannot be readily explained by content of
transgenic material.
Differences in BAC integrity were also found for the
420L19-LacZ lines. Lines 215, 237, and 267 all had the full
complement of BAC markers E–H and J (supplementary
Fig. S3). The finding that these three lines largely reflect the
same transgenic sequences is consistent with the similar LacZ
expression patterns in these embryos. We did not detect any
major deletions and we conclude that the lack of central or
distal autopod expression, or late onset of the expression are
consistent with true insufficiency of 420L19-LacZ to perform
these enhancer functions and that the regulatory elements
responsible for these domains must lie outside of this clone.
Line 273 also contains all of the tested markers, yet no limb or
genital bud staining was found for this line. We hypothesize
that potential limb and genital bud expression capabilities in
this transgene are likely being silenced by the site of integra-
tion or the overall integrated structure is not conducive to
expression. Line 222 was only positive for markers E and J.
The absence of markers F and G indicate a probable deletion
of mmA13CNS in this transgene, likely explaining the
absence of central nervous system staining in this line.
DISCUSSION
Genital bud enhancer(s)
Our data demonstrate that 347D13-LacZ is sufficient for
Hoxa13-like genital bud expression at stages E10.5–E13.5.
420L19-LacZ is sufficient for Hoxa13-like genital bud expres-
sion at stages E10.5–E11.5 (Fig. 3). This indicates that the
region of intersection of the two overlapping transgenes is
sufficient for E10.5–E11.5 Hoxa13-like genital bud expression
(Fig. 4). While the genital bud expression from E12.5–E13.5
in the 420L19-LacZ lines was consistently posteriorized, vari-
ability was found for the E11.5 expression domain which
shows the potential of the transgene to drive two types of
expression. Line 215 was sufficient for entire E11.5 genital bud
expression, whereas all of the remaining expressing lines had a
posteriorized expression domain even in the context of the
same transgenic sequence content (similar to Fig. 4, C vs. C0).
The ability of the same transgene to be expressed in either a
complete or incomplete manner suggests the presence of an
intact regulatory element whose function is perhaps context
dependent. This is further demonstrated by the results from
347D13-LacZ. This transgene was shown to be sufficient for
genital bud expression at all stages (line 710 and founder
embryo 18), yet founder embryo 69 had a posteriorized gen-
ital bud expression domain (similar to Fig. 4E0). We hypoth-
esize based on this data that a regulatory element(s) sufficient
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forHoxa13-like genital bud expression is contained within the
 114kb fragment in common between BACs 347D13 and
420L19, yet our data does not exclude redundant enhancer
contribution from outside the 114kb domain. We also
hypothesize that the enhancer(s) within the BACs is sensitive
to genomic context and is capable of being expressed in either
a Hoxa13-like domain or in a restricted posterior domain
between E11.5 and E13.5.
Distal limb enhancer(s)
We propose a model to combine the expression data we have
obtained from our 347D13-LacZ and 420L19-LacZ trans-
genic embryos that requires enhancers influencing the onset of
expression, proximal/distal and anterior/posterior boundaries,
and tissue expression subdomains. We considered the
commonalities in Hoxa13-related limb expression between
the two transgenes, because the enhancer(s) directing that
expression should be localized to the overlapping BAC
sequences. Generally speaking, both BACs are capable of
directing distal autopod expression between E11.5 and E13.5.
This expression is Hoxa13-like in the anterior/posterior do-
mains, the dorsal/ventral domains, as well as at the proximal
boundary. We hypothesize that an enhancer(s) within this
 114kb fragment is responsible for E11.5 expression onset
and related expression domains and boundaries.
Our data suggests that at least one additional enhancer is
located within the  107kb fragment of 347D13 that does
not overlap with 420L19, though we have not determined
whether it functions autonomously or cooperatively with the
enhancer(s) in the adjacent  114kb fragment. We showed
that the 347D13-LacZ transgene was expressed in the auto-
pod at stage E10.5 and it was expressed in the central and
distal-most boundary of the autopod. This stage of expression
onset and these tissue sub-domains were never observed in
any of seven 420L19-LacZ lines, thus our model proposes the
existence of an enhancer(s) in this  107kb region respon-
sible for this expression. Effectively, the remote enhancers for
Hoxa13-like limb expression fall within two separate, yet still
broad regions. A Hoxa13 regulatory network contingent
upon multiple remote enhancers is supported by the recent
finding of a similar, multi-component system upstream of the
HoxD locus (Gonzalez et al. 2007).
Evolution of embryonic distal limb and genital
bud expression domains
We recognize the experiments in this report are testing the
sufficiency of putative regulatory elements that are compara-
ble to, but not proven to be biologically involved in, Hoxa13
gene expression. Our prior work showed that Hoxa13, Evx1,
Hibadh, Tax1bp1, and Jazf1 all have distal autopod and
genital bud expression from E10.5 through E13.5 (Lehoczky
et al. 2004), and we have no direct evidence that the sequences
we are mapping are not merely local regulatory elements
specific to one of these genes. Yet, we interpret our LacZ
reporter data as expression from regional enhancers rather
than gene-specific enhancers primarily due to our original
HoxA/D paralogous sequence comparison that led us to focus
on this region (ParaCNS415).
The similarities in expression and function of the posterior
HoxA/D genes, combined with their common genomic origin,
are most parsimonious with the existence of a limb/genital, or
more simply a distal appendage, regulatory module before the
HoxA/D cluster duplication. Under this model, the remote
regulation that exists for the extant posterior HoxA and
posterior HoxD genes resulted from divergence over the
course of vertebrate evolution. Presumably, introduction and/
or degradation of genes upstream of the HoxA and HoxD
clusters led to the extremely different upstream genomic
neighborhoods (Lehoczky et al. 2004), yet the enhancers
required for distal limb and genital bud expression were
retained. The distinct upstream regions inevitably placed
different evolutionary constraints on these pre-existing regu-
latory sequences. On the HoxD chromosome, the distal limb
enhancers were recently mapped to two discrete, remote loci:
GCR and Prox (Gonzalez et al. 2007). GCR exhibits sequence
conservation to the HoxA upstream region corresponding to
mmA13CNS (Lehoczky et al. 2004), but there is no para-
logous Prox element in the HoxA locus detectable by stan-
dard sequence conservation. Absence of conservation between
the Prox HoxD region and any sequence at the HoxA locus
does not preclude the existence of a functionally comparable
enhancer element at the HoxA locus. One explanation could
be that Prox and a functionally paralogous enhancer at the
HoxA locus have diverged since the HoxA/D cluster dupli-
cation thus escaping the sequence conservation thresholds.
GCR and Prox enhancers are proposed to interact with
two genes (Evx2 and Lnp) in addition to the posterior HoxD
genes. Similarly, on theHoxA chromosome our data supports
the existence of at least two discrete enhancers functioning in
long-range regulation. Yet distinct from the HoxD regulatory
organization, which has remote enhancers positioned within a
gene desert, the HoxA limb/genital bud remote enhancers are
within a gene neighborhood. The remote HoxA enhancers
that we infer from our data appear to interact, bidirectionally,
with four other genes (Evx1, Hibadh, Tax1bp1, and Jazf1) in
addition to Hoxa13. Future work should identify the smallest
functional sequence elements within these broad, remote up-
stream HoxA domains, and compare their function(s) with
GCR and Prox via endogenous deletion of the elements in
mice.
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SUPPLEMENTARY MATERIALS
The following material is available for this article online:
Fig. S1. Endogenous Hoxa13 expression is revealed in
mouse embryos using RNA in situ hybridization from E10.5
through E13.5 in the developing limbs and genital bud.
Fig. S2. X-gal stained forelimbs from all 420L19-LacZ
(top) and 347D13-LacZ (bottom) expressing, transgenic lines
or founders (f). Autopods are positioned distal to the top and
anterior to the left. Interline variability for 420L19-LacZ is
shown for stages E11.5 through E13.5 as no line had any
forelimb expression at E10.5. Line 710 (347D13-LacZ) shows
LacZ expression domains when compared to founder em-
bryos 69 and 18 at stages E11.5–E12.5. None5we observed
no expression in forelimb; NA5not available.
Fig. S3. BAC transgene integrity analysis. Transgenic
DBA1/1animals were genotyped at the indicated markers
excluding E and J for the 347D13-LacZ lines and markers
E-H, and J for 420L19-LacZ lines. Markers are: A5347D13-
T7 insert/vector junction; B5RS29851258; C5RS29857058;
D5RS30707421; E5420L19-T7 insert/vector junction;
F5RS13478755; G5RS29863749; H5RS30170317;
I5347D13-SP6 insert/vector junction; and J5420L19-SP6
insert/vector junction. Arrowhead represents location of
mmA13CNS. Solid dots indicated the transgenic insert is
positive for that marker and X’s depict absence of the marker.
Lines 250 and 268 were not included in this analysis due to
multiple unsuccessful attempts to generate transgenic DBA1/
1animals.
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Table S1. BAC copy number of transgenic lines.
This material is available as part of the online article from:
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-
142X.2008.00253.x (This link will take you to the article
abstract).
Please note: Blackwell Publishing is not responsible for
the content or functionality of any supplementary materials
supplied by the authors. Any queries (other than missing
material) should be directed to the corresponding author for
the article.
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